medwireNews: The EMA’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending that the indication for secukinumab should be expanded to include two types of juvenile idiopathic arthritis.
The interleukin-17A inhibitor was previously approved for psoriatic arthritis (PsA), ankylosing spondylitis, nonradiographic axial spondyloarthritis, and adult and pediatric plaque psoriasis.
Following the latest announcement, it may now be given to patients aged 6 years and older with active juvenile PsA or enthesitis-related arthritis (ERA) and an inadequate response or intolerance to conventional therapy. Secukinumab can be given as monotherapy or in combination with methotrexate.
The efficacy of secukinumab in children and adolescents with juvenile PsA or ERA was demonstrated in the JUNIPERA trial.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group